America’s AI Boom Has a Trade Policy Blind Spot
The AI data center buildout has exposed three distinct failures in U.S. trade and industrial policy.
On Capitol Hill, China Themes Increasingly Center On Trade Theft, Espionage, IP Violations
How did China become a near peer competitor with the U.S. on everything from computers to AI platforms to space? Theft and IP violations.
CPA Warns of Critical U.S. Vulnerabilities in Antibiotic Supply Chain, Calls for Action to Protect and Rebuild Domestic and Allied Production
Without secure upstream API and 6-APA production, the United States does not have true antibiotic supply security. With the right policy framework and close coordination with European partners, we can rebuild domestic capacity, strengthen allied production, and secure essential medicines for the long term.
In Hearing, Congress Says China Stealing American AI Models, But Witnesses Focus On More Obvious Problems
Leadership of the House Select Committee on the CCP is convinced China is stealing American AI models. That’s why China has an OpenAI rival, called DeepSeek, and the Europeans have nothing.
CPA: Solar Trade Case Preliminary Duties Underscore Need for Full Supply Chain Action in Polysilicon 232
The findings reinforce a persistent pattern in global solar trade: when enforcement actions target specific countries, production and shipments shift to new jurisdictions.
War, AI, and Grid Stress: Why This Is Solar Power’s Moment
The war in Iran is solar power’s Covid moment.
Tariffs as Budget Pay-Fors: Three Revenue Options for Congress
As the Congressional Budget Office (CBO) projects a $1.9 trillion federal deficit for fiscal year 2026, Congress is under increasing pressure to identify durable budget pay-fors. In most cases, that discussion quickly narrows to three familiar choices: raise domestic taxes, cut spending, or continue borrowing more. But tariffs warrant more serious consideration.
Warnings Of China Taking Lead In Biopharma Future In Latest Senate Hearing
China holds a rapidly expanding position in the global biologics and biosimilars market, driven by heavy government support, regulatory reforms, and massive investments in biotech hubs like Shanghai and Suzhou.
CPA Submits Comments to USITC on China’s Permanent Normal Trade Relations
Revoking PNTR for China would move Chinese imports onto an average effective Column 2 tariff rate of 38.9 percent, helping rebalance trade, restore domestic production capacity, and reduce strategic dependence on an increasingly adversarial economic system.
CPA Applauds FDA Proposal to Strengthen U.S. Generic Drug Manufacturing and Supply Chain Integrity
CPA welcomes new proposals from the Food and Drug Administration (FDA) aimed at rebuilding domestic generic drug manufacturing, strengthening oversight of foreign pharmaceutical production, and improving supply chain transparency.
